Published in J Urol on September 01, 1997
Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol (2001) 2.15
The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn (2000) 1.74
Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification. Clin Cancer Res (2011) 1.50
Time to abandon testing for microscopic haematuria in adults? BMJ (2003) 1.39
Critical evaluation of urinary markers for bladder cancer detection and monitoring. Rev Urol (2008) 1.05
Molecular screening for bladder cancer: progress and potential. Nat Rev Urol (2010) 0.97
Quantitative estimation of Serum Fibrinogen Degradation Product levels in Oral Premalignant and Malignant lesions. J Int Oral Health (2013) 0.93
Urine cytology and adjunct markers for detection and surveillance of bladder cancer. Am J Transl Res (2010) 0.92
Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma. Rev Urol (2001) 0.82
Proteomics analysis of urine reveals acute phase response proteins as candidate diagnostic biomarkers for prostate cancer. Proteome Sci (2015) 0.79
Early bladder cancer: concept, diagnosis, and management. Int J Clin Oncol (2006) 0.77
Renal-cell carcinoma. N Engl J Med (1996) 11.46
Apolipoprotein B-48 is the product of a messenger RNA with an organ-specific in-frame stop codon. Science (1987) 4.98
Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol (1992) 4.79
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol (1976) 4.37
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet (2001) 3.39
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology (2008) 2.87
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 2.72
Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem (1997) 2.53
Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol (1993) 2.50
Tumor therapy with targeted atomic nanogenerators. Science (2001) 2.48
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res (1998) 2.38
Autogenous immunity to endogenous RNA tumor virus. Radioimmune precipitation assay of mouse serum antibody levels. J Exp Med (1973) 2.31
Localization of 125I-labeled antigen in germinal centers of mouse spleen: histologic and ultrastructural autoradiographic studies of the secondary immune reaction. J Immunol (1968) 2.21
Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proc Natl Acad Sci U S A (1988) 2.20
The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain (2005) 2.17
Autogenous immunity to endogenous RNA tumor virus. Identification of antibody reactivity to select viral antigens. J Exp Med (1974) 2.10
A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N Engl J Med (1991) 2.07
Localization of the prostatic apex for radiation therapy using implanted markers. Int J Radiat Oncol Biol Phys (1993) 2.07
Guidelines for the treatment of acute ischaemic stroke. Neurologia (2011) 2.05
Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol (1986) 2.01
Neurological channelopathies. Postgrad Med J (2005) 1.98
Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal-cell carcinoma. Lancet (1990) 1.94
Treatment of rheumatoid arthritis with oral type II collagen. Results of a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum (1998) 1.93
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. Int J Cancer (1999) 1.91
Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain (2007) 1.91
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res (2000) 1.91
The ultrastructure of antigen localization and viruslike particles in mouse spleen germinal centers. Exp Mol Pathol (1968) 1.86
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res (2000) 1.85
Familial lipoprotein disorders in patients with premature coronary artery disease. Circulation (1992) 1.84
A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain (1999) 1.84
Rapid detection of bladder cancer: a comparative study of point of care tests. J Urol (1997) 1.80
Electron microscopic autoradiography of germinal center cells in mouse spleen. J Cell Biol (1965) 1.78
Liposarcoma of the spermatic cord: report of 6 cases and review of the literature. J Urol (1995) 1.76
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1.74
Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology (1996) 1.72
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Chemoprevention of urological cancer. J Urol (1999) 1.70
Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility. Mol Biol Cell (2001) 1.68
The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain (2009) 1.65
Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol (2000) 1.64
Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology (2010) 1.59
Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol (2008) 1.55
Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res (1990) 1.53
Selective glutathione depletion of mitochondria by ethanol sensitizes hepatocytes to tumor necrosis factor. Gastroenterology (1998) 1.52
The pharmacokinetics of yohimbine in man. Eur J Clin Pharmacol (1987) 1.50
Hyperprolactinemia and impotence: why, when and how to investigate. J Urol (1989) 1.50
Purification and properties of pyruvate dehydrogenase phosphatase from bovine heart and kidney. Biochemistry (1982) 1.50
Polypeptides of mammalian oncornaviruses. III. Localization of p 15 and reactivity with natural antibody. Virology (1975) 1.48
Immunotherapy of cancer: regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl Cancer Inst (1972) 1.48
125I implantation for carcinoma of prostate. Further follow-up of first 100 cases. Urology (1982) 1.47
Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. I. Tumor growth and metastasis. J Natl Cancer Inst (1972) 1.47
Rapid monoclonal antibody-based enzyme-linked immunosorbent assay for detection of Listeria in food products. J Assoc Off Anal Chem (1988) 1.46
Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry (2009) 1.46
Cimetidine in the treatment of interstitial cystitis. Urology (1994) 1.45
Topical nitroglycerin: a potential treatment for impotence. J Urol (1989) 1.44
Monoclonal antibodies specific for prothrombin fragment 1.2 and their use in a quantitative enzyme-linked immunosorbent assay. Clin Chem (1993) 1.44
The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel. Eur Urol (2005) 1.42
GSH transport in mitochondria: defense against TNF-induced oxidative stress and alcohol-induced defect. Am J Physiol (1997) 1.42
Accessory and ectopic scrota. Urology (1977) 1.40
Molecular genetic dissection of the sex-specific and vital functions of the Drosophila melanogaster sex determination gene fruitless. Genetics (2001) 1.39
Autogenous immunity to endogenous RNA tumor virus antigens in mice with a low natural incidence of lymphoma. Cancer Res (1972) 1.39
Simultaneous pulmonary and renal malignancy. Chest (1990) 1.39
Diagnosing impotence. Can Fam Physician (1983) 1.39
Papillary necrosis following phenylbutazone ingestion. Arch Surg (1971) 1.39
Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology (1999) 1.36
The clinical, histochemical, and molecular spectrum of PEO1 (Twinkle)-linked adPEO. Neurology (2010) 1.36
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol (1993) 1.35
Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology (1995) 1.35
Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol (1985) 1.34
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer (1993) 1.31
Visualization of minute centers of viral infection in unfixed cell cultures by an enzyme-linked antibody assay. J Immunol Methods (1981) 1.31
Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. J Androl (2008) 1.31
Effects of freezing on marrow stem cell suspensions: interactions of cooling and warming rates in the presence of PVP, sucrose, or glycerol. Cryobiology (1970) 1.30
Overall cardiovascular profile of sildenafil citrate. Am J Cardiol (1999) 1.30
Changes induced by lactic dehydrogenase virus in thymus and thymus-dependent areas of lymphatic tissue. J Immunol (1972) 1.30
Inhalant, marijuana, and alcohol abuse among barrio children and adolescents. Int J Addict (1979) 1.30
Renal cell carcinoma as an incidental finding. J Urol (1985) 1.29
Uptake of 2-deoxy-2-[18F]fluoro-D-glucose in the normal testis: retrospective PET study and animal experiment. Ann Nucl Med (1997) 1.29
Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. J Urol (1980) 1.29
The effect of antigen competition on both the primary and secondary immune capacity in mice. J Immunol (1970) 1.27
Neural defects in Jarcho-Levin syndrome. J Child Neurol (1989) 1.27
Double-blind trial of yohimbine in treatment of psychogenic impotence. Lancet (1987) 1.26
Prospectively randomized trial of adjuvant active-specific immunotherapy for human colorectal cancer. Cancer (1985) 1.25
A stage specific approach to tumor surveillance after radical cystectomy for transitional cell carcinoma of the bladder. J Urol (1999) 1.24
Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur J Nucl Med (1997) 1.24
Effect of chronic ethanol feeding on glutathione and functional integrity of mitochondria in periportal and perivenous rat hepatocytes. J Clin Invest (1994) 1.22
ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Int J Impot Res (2008) 1.22
Chloride channel myotonia: exon 8 hot-spot for dominant-negative interactions. Brain (2007) 1.21
Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. 1976. J Urol (2002) 1.21
Outcome analysis of 42 cases of renal angiomyolipoma. J Urol (1994) 1.21
Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June 2008. Neuromuscul Disord (2010) 1.21
Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer Res (1997) 1.21
A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy. Am J Hum Genet (1999) 1.20
Immunotherapy for bladder cancer. Curr Urol Rep (2001) 1.20
What causes paramyotonia in the United Kingdom? Common and new SCN4A mutations revealed. Neurology (2008) 1.19